|
1. |
Epidemiology of Covid-19 in a Long-Term Care Facility in King County, Washington.
|
|
2. |
The Invisible Hand — Medical Care during the Pandemic.
|
|
3. |
Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study.
|
|
4. |
Real-Time Quantitative PCR Assays for Detection and Monitoring of Pathogenic Human Viruses in Immunosuppressed Pediatric Patients.
|
|
5. |
Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR.
|
|
6. |
A novel coronavirus outbreak of global health concern.
|
|
7. |
Viral load of SARS-CoV-2 in clinical samples.
|
|
8. |
Viral Load Kinetics of SARS-CoV-2 Infection in First Two Patients in Korea.
|
|
9. |
SARSCoV-2 (Cell).
|
|
10. |
Laboratory testing for coronavirus disease (COVID-19) in suspected human cases.
|
|
11. |
Standard Operating Procedure For Detection of 2019 novel coronavirus (2019-nCoV) in suspected human cases by rRT-PCR : First Line Screening assay.
|
|
12. |
Severe acute respiratory illness surveillance for coronavirus disease 2019, India, 2020.
|
|
13. |
Corona Virus disease 2019 (COVID-19) Situation Report-80.
|
|
14. |
Chloroquine and hydroxychloroquine in COVID-19.
|
|
15. |
Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia.
|
|
16. |
Use of Hydroxychloroquine and Chloroquine During the COVID-19 Pandemic: What Every Clinician Should Know.
|
|
17. |
How Sewage Could Reveal True Scale Of Coronavirus Outbreak.
|
|
18. |
Guide to understand the 2019 NOVEL CORONAVIRUS.
|
|
19. |
Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1.
|
|
20. |
Coronavirus disease 2019 (COVID-19) : The right clinical information, right where it's needed.
|
|
21. |
Face masks for the public during the covid-19 crisis.
|
|
22. |
Compassionate Use of Remdesivir for Patients with Severe Covid-19.
|
|
23. |
A Shift on the Front Line.
|
|
24. |
Disease Control, Civil Liberties, and Mass Testing — Calibrating Restrictions during the Covid-19 Pandemic.
|
|
25. |
Not Dying Alone- Modern Compassionate Care in the COVID-19 Pandemic.
|
|
26. |
Drug Evaluation during the Covid-19 Pandemic.
|
|
27. |
COVID-19, diabetes mellitus and ACE2: The conundrum.
|
|
28. |
The FDA-approved Drug Ivermectin inhibits the replication of SARS-1 CoV-2 in vitro.
|
|
29. |
Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19).
|
|
30. |
Guidelines on Establishment of Virology Laboratory in Developing Countries.
|
|
31. |
COVID-19 and the cardiovascular system.
|
|
32. |
Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study.
|
|
33. |
CT screening for early diagnosis of SARS-CoV-2 infection.
|
|
34. |
Flooded by the torrent: the COVID-19 drug pipeline.
|
|
35. |
COVID-19 in the USA: a question of time.
|
|
36. |
Prediction models for diagnosis and prognosis in Covid-19.
|
|
37. |
Prediction models for diagnosis and prognosis of covid-19 infection: systematic review and critical appraisal.
|
|
38. |
Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1.
|
|
39. |
How to Obtain a Nasopharyngeal Swab Specimen.
|
|
40. |
Guillain–Barré Syndrome Associated with SARS-CoV-2.
|
|
41. |
Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19.
|
|
42. |
Forecast of COVID-19 Case in India by Lockdown Patterns.
|
|
43. |
Age-structured impact of social distancing on the COVID-19 epidemic in India.
|
|
44. |
Dentistry and coronavirus (COVID-19) – moral decision-making.
|
|
45. |
Universal Screening for SARS-CoV-2 in Women Admitted for Delivery.
|
|
46. |
Prediction for COVID-19 Outbreak in India uing Epidemiological Models.
|
|
47. |
The architecture of SARS-CoV-2 transcriptome.
|
|
48. |
Universal Screening for SARS-CoV-2 in Women Admitted for Delivery.
|
|
49. |
Renin–Angiotensin–Aldosterone System Inhibitors in Patients with Covid-19.
|
|
50. |
Ten Weeks to Crush the Curve.
|
|
51. |
Myocarditis in a patient with COVID-19: a cause of raised troponin and ECG changes.
|
|
52. |
Travel restrictions hampering COVID-19 response.
|
|
53. |
Modelling can only tell us so much: politics explains the rest.
|
|
54. |
The Penumbra: COVID-19 fault lines.
|
|
55. |
India under COVID-19 lockdown.
|
|
56. |
Presymptomatic SARS-CoV-2 Infections and Transmission in a Skilled Nursing Facility.
|
|
57. |
Asymptomatic Transmission, the Achilles’ Heel of Current Strategies to Control Covid-19.
|
|
58. |
Covid-19 — A Reminder to Reason.
|
|
59. |
Mild or Moderate Covid-19.
|
|
60. |
Early dynamics of transmission and control of COVID-19: a mathematical modelling study.
|
|
61. |
SARS-CoV-2: virus dynamics and host response.
|
|
62. |
|
|
63. |
|
|
64. |
|
|
65. |
Physician Burnout, Interrupted.
|
|
66. |
Cardiovascular Disease, Drug Therapy,and Mortality in Covid-19.
|
|
67. |
Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19.
|
|
68. |
Association between Angiotensin Blockade and Incidence of Influenza in the United Kingdom.
|
|
69. |
Clasification of the cutaneous manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases.
|
|
70. |
What policy makers need to know about COVID-19 protective immunity.
|
|
71. |
How to Discover Antiviral Drugs Quickly.
|
|
72. |
PCR screening of asymptomatic healthcare workers at London hospital.
|
|
73. |
Riding the coronacoaster of uncertainty.
|
|
74. |
Estimates of the severity of coronavirus disease 2019: a model-based analysis.
|
|
75. |
Controversies of renin–angiotensin system inhibition during the COVID-19 pandemic.
|
|
76. |
Hypertension, renin–angiotensin–aldosterone system inhibition, and COVID-19.
|
|
77. |
Interferon beta-1b for COVID-19.
|
|
78. |
The art of medicine: Has COVID-19 subverted global health?
|
|
79. |
Suppressing the Epidemic in New South Wales.
|
|
80. |
Swabs Collected by Patients or Health Care Workers for SARS-CoV-2 Testing.
|
|
81. |
Severe Covid-19: The Clinical Problem.
|
|
82. |
COVID-19: Attacks the 1-Beta Chain of Hemoglobin and Captures the Porphyrin to Inhibit Human Heme Metabolism.
|
|
83. |
|
|
84. |
Men’s health: COVID-19 pandemic highlights need for overdue policy action.
|
|
85. |
Solidarity in the wake of COVID-19: reimagining the International Health Regulations.
|
|
86. |
An mRNA Vaccine against SARS-CoV-2 — Preliminary Report.
|
|
87. |
Pandemic peak SARS-CoV-2 infection and seroconversion rates in London frontline health-care workers.
|
|
88. |
The Covid-19 Vaccine-Development Multiverse.
|
|
89. |
An mRNA Vaccine against SARS-CoV-2 — Preliminary Report.
|
|
90. |
Asymptomatic SARS-CoV-2 infection.
|
|
91. |
Asymptomatic Transmission, the Achilles’ Heel of Current Strategies to Control Covid-19.
|
|
92. |
Saliva or Nasopharyngeal Swab Specimens for Detection of SARS-CoV-2.
|
|
93. |
Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine.
|
|
94. |
COVID-19 in India: The dangers of false optimism.
|
|
95. |
Phase 1–2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine.
|
|
96. |
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.
|
|
97. |
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.
|
|
98.
|
Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers. |